KALA BIO, Inc.KALAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative ophthalmology therapies. It has a pipeline of product candidates addressing both common and rare eye diseases, targeting unmet medical needs and serving patients and healthcare providers mainly across the United States.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 19.99% | 891.3K | ▲ +10.00pp | 2024-06-28 |
| ADAR1 Capital Management, LLC | 9.99% | 477.7K | — | 2024-11-14 |
| SR One Capital Fund II Aggregator, LP | 9.99% | 445.6K | — | 2024-07-08 |
| Millennium Management LLC | 5.00% | 135.1K | — | 2024-02-16 |
| Integrated Core Strategies | 4.90% | 130.7K | — | 2024-01-29 |
| Longitude Capital Partners II, LLC | 2.30% | 57.5K | — | 2023-10-18 |
| Checkpoint Capital | 0.00% | 483.1M | ▼ -9.70pp | 2024-02-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.